Quantum Biopharma Ltd.
Graphique
Bon à savoir : L’investissement en actions présente un potentiel de rendement à long terme, mais implique également un risque de perte, pouvant aller jusqu’à la totalité du capital investi. Les performances passées de cette action ne sont pas un indicateur fiable des résultats futurs. Les données fournies par des sources externes n’ont pas été modifiées par Saxo. Voir la clause de non-responsabilité.
À propos Quantum Biopharma Ltd.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
/ 